---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-065292"
form_type: "8-K"
ticker: "AZTA"
cik: "0000933974"
company_name: "Azenta, Inc."
filed_at: "2026-10-07T12:01:12+00:00"
generated_at: "2026-10-12T16:00:50.755851+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Azenta restructures Multiomics: closing 3 North American lab sites, $11-13M charges, $11M annual savings

## Summary
- Board approved the plan on October 5, 2026 to consolidate the North American lab network; employee notifications began October 6, 2026.
- Closing three Multiomics laboratory sites in North America plus workforce reductions; actions expected substantially complete by March 31, 2027.
- Estimated pre-tax charges of $11.0M-$13.0M: ~$9.0M impairment plus ~$3.0M severance/other; future cash expenditures ~$7.0M.
- Approximately $9.0M impairment covers operating lease right-of-use assets and leasehold improvements at leased facilities Azenta expects to exit before lease expiry.
- Expects ~$11.0M annualized cost savings once fully implemented; charges mostly recognized in fiscal year ending September 30, 2027.

## SEC filing metadata
- accession: 0001628280-26-065292
- form_type: 8-K
- ticker: AZTA
- cik: 0000933974
- company_name: Azenta, Inc.
- filed_at: 2026-10-07T12:01:12+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 2.05, 2.06, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/933974/000162828026065292/0001628280-26-065292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/933974/000162828026065292/azta-20261005.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-065292
- JSON: https://secwatch.observer/filing/0001628280-26-065292.json
- Plain text: https://secwatch.observer/filing/0001628280-26-065292.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.